Literature DB >> 1850009

Pathways of activation of the Epstein-Barr virus productive cycle.

A J Sinclair1, M Brimmell, F Shanahan, P J Farrell.   

Abstract

The promoter for the 2.8-kb RNA of Epstein-Barr virus encoding BZLF1 and BRLF1 was identified and shown to be activated by both BZLF1 and BRLF1 but not by 12-O-tetradecanoylphorbol-13-acetate. Site-directed mutagenesis suggests that two binding sites for BZLF1 within the promoter contribute to the transactivation by BZLF1. The early kinetics of induction of the 2.8- and 1.0-kb RNAs encoding BZLF1 and BRLF1 in Akata cells treated with anti-immunoglobulin indicate that both RNAs appear within 60 min. The results indicate some likely pathways of activation of Epstein-Barr virus productive cycle gene expression.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1850009      PMCID： PMC240572     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  34 in total

1.  The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle.

Authors:  C M Rooney; D T Rowe; T Ragot; P J Farrell
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.

Authors:  M Buisson; E Manet; M C Trescol-Biemont; H Gruffat; B Durand; A Sergeant
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

3.  Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells.

Authors:  M Biggin; M Bodescot; M Perricaudet; P Farrell
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

4.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment.

Authors:  K Takada; N Shimizu; S Sakuma; Y Ono
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

6.  The role of the leucine zipper in the fos-jun interaction.

Authors:  T Kouzarides; E Ziff
Journal:  Nature       Date:  1988-12-15       Impact factor: 49.962

7.  A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen.

Authors:  J M Hardwick; P M Lieberman; S D Hayward
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

8.  The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites.

Authors:  G Urier; M Buisson; P Chambard; A Sergeant
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

9.  Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators.

Authors:  E Manet; H Gruffat; M C Trescol-Biemont; N Moreno; P Chambard; J F Giot; A Sergeant
Journal:  EMBO J       Date:  1989-06       Impact factor: 11.598

10.  Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos.

Authors:  P J Farrell; D T Rowe; C M Rooney; T Kouzarides
Journal:  EMBO J       Date:  1989-01       Impact factor: 11.598
View more
  70 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Nucleoprotein structure of immediate-early promoters Zp and Rp and of oriLyt of latent Epstein-Barr virus genomes.

Authors:  Hans Helmut Niller; Daniel Salamon; Jörg Uhlig; Stefanie Ranf; Marcus Granz; Fritz Schwarzmann; Hans Wolf; Janos Minarovits
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.

Authors:  C D Darr; A Mauser; S Kenney
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Promoter sequences required for reactivation of Epstein-Barr virus from latency.

Authors:  Ulrich K Binné; Wolfgang Amon; Paul J Farrell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Identification of protein tyrosine kinases required for B-cell- receptor-mediated activation of an Epstein-Barr Virus immediate-early gene promoter.

Authors:  Sandra Lavens; Emmanuel A Faust; Fang Lu; Michele Jacob; Messele Leta; Paul M Lieberman; Ellen Puré
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.

Authors:  Amy L Ellis; Zhenxun Wang; Xianming Yu; Janet E Mertz
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

9.  Repression of CIITA by the Epstein-Barr virus transcription factor Zta is independent of its dimerization and DNA binding.

Authors:  Nicolae Balan; Kay Osborn; Alison J Sinclair
Journal:  J Gen Virol       Date:  2015-12-11       Impact factor: 3.891

10.  Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.

Authors:  Wangrong Wen; Dai Iwakiri; Koji Yamamoto; Seiji Maruo; Teru Kanda; Kenzo Takada
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.